68Ga-FAPI PET/CT: Tracer uptake in 28 different kinds of cancer

Clemens Kratochwil, Paul Flechsig, Thomas Lindner, Labidi Abderrahim, Annette Altmann, Walter Mier, Sebastian Adeberg, Hendrik Rathke, Manuel Röhrich, Hauke Winter, Peter K. Plinkert, Frederik Marme, Matthias Lang, Hans Ulrich Kauczor, Dirk Jäger, Jürgen Debus, Uwe Haberkorn, Frederik L. Giesel

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

The recent development of quinoline-based PET tracers that act as fibroblast-activation-protein inhibitors (FAPIs) demonstrated promising preclinical and clinical results. FAP is overexpressed by cancer-associated fibroblasts of several tumor entities. Here, we quantify the tumor uptake on 68Ga-FAPI PET/CT of various primary and metastatic tumors to identify the most promising indications for future application. Methods: 68Ga-FAPI PET/CT scans were requested by various referring physicians according to individual clinical indications that were considered insufficiently covered by 18F-FDG PET/CT or other imaging modalities. All PET/CT was performed 1 h after injection of 122–312 MBq of 68Ga-FAPI-04. We retrospectively identified 80 patients with histopathologically proven primary tumors or metastases or radiologically unequivocal metastatic lesions of histologically proven primary tumors. Tumor uptake was quantified by SUVmax and SUVmean (60% isocontour). Results: Eighty patients with 28 different tumor entities (54 primary tumors and 229 metastases) were evaluated. The highest average SUVmax (.12) was found in sarcoma, esophageal, breast, cholangiocarcinoma, and lung cancer. The lowest 68Ga-FAPI uptake (average SUVmax, 6) was observed in pheochromocytoma, renal cell, differentiated thyroid, adenoid cystic, and gastric cancer. The average SUVmax of hepatocellular, colorectal, head–neck, ovarian, pancreatic, and prostate cancer was intermediate (SUV 6–12). SUV varied across and within all tumor entities. Because of low background in muscle and blood pool (SUVmax , 2), the tumor-to-background contrast ratios were more than 3-fold in the intermediate and more than 6-fold in the high-intensity uptake group. Conclusion: Several highly prevalent cancers presented with remarkably high uptake and image contrast on 68Ga-FAPI PET/CT. The high and rather selective tumor uptake may open up new applications for noninvasive tumor characterization, staging examinations, or radioligand therapy.

Original languageEnglish (US)
Pages (from-to)801-805
Number of pages5
JournalJournal of Nuclear Medicine
Volume60
Issue number6
DOIs
StatePublished - Jun 1 2019

Fingerprint

Fibroblasts
Neoplasms
Proteins
Neoplasm Metastasis
Adenoids
Cholangiocarcinoma
Neoplasm Staging
Fluorodeoxyglucose F18
Pheochromocytoma
Pancreatic Neoplasms
Sarcoma
Ovarian Neoplasms
Stomach Neoplasms
Colorectal Neoplasms
Lung Neoplasms
Prostatic Neoplasms
Thyroid Gland
Breast Neoplasms
Physicians
Kidney

Keywords

  • Breast cancer
  • Colorectal cancer
  • FAPI
  • Lung cancer
  • PET/CT

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Kratochwil, C., Flechsig, P., Lindner, T., Abderrahim, L., Altmann, A., Mier, W., ... Giesel, F. L. (2019). 68Ga-FAPI PET/CT: Tracer uptake in 28 different kinds of cancer. Journal of Nuclear Medicine, 60(6), 801-805. https://doi.org/10.2967/jnumed.119.227967

68Ga-FAPI PET/CT : Tracer uptake in 28 different kinds of cancer. / Kratochwil, Clemens; Flechsig, Paul; Lindner, Thomas; Abderrahim, Labidi; Altmann, Annette; Mier, Walter; Adeberg, Sebastian; Rathke, Hendrik; Röhrich, Manuel; Winter, Hauke; Plinkert, Peter K.; Marme, Frederik; Lang, Matthias; Kauczor, Hans Ulrich; Jäger, Dirk; Debus, Jürgen; Haberkorn, Uwe; Giesel, Frederik L.

In: Journal of Nuclear Medicine, Vol. 60, No. 6, 01.06.2019, p. 801-805.

Research output: Contribution to journalArticle

Kratochwil, C, Flechsig, P, Lindner, T, Abderrahim, L, Altmann, A, Mier, W, Adeberg, S, Rathke, H, Röhrich, M, Winter, H, Plinkert, PK, Marme, F, Lang, M, Kauczor, HU, Jäger, D, Debus, J, Haberkorn, U & Giesel, FL 2019, '68Ga-FAPI PET/CT: Tracer uptake in 28 different kinds of cancer' Journal of Nuclear Medicine, vol. 60, no. 6, pp. 801-805. https://doi.org/10.2967/jnumed.119.227967
Kratochwil C, Flechsig P, Lindner T, Abderrahim L, Altmann A, Mier W et al. 68Ga-FAPI PET/CT: Tracer uptake in 28 different kinds of cancer. Journal of Nuclear Medicine. 2019 Jun 1;60(6):801-805. https://doi.org/10.2967/jnumed.119.227967
Kratochwil, Clemens ; Flechsig, Paul ; Lindner, Thomas ; Abderrahim, Labidi ; Altmann, Annette ; Mier, Walter ; Adeberg, Sebastian ; Rathke, Hendrik ; Röhrich, Manuel ; Winter, Hauke ; Plinkert, Peter K. ; Marme, Frederik ; Lang, Matthias ; Kauczor, Hans Ulrich ; Jäger, Dirk ; Debus, Jürgen ; Haberkorn, Uwe ; Giesel, Frederik L. / 68Ga-FAPI PET/CT : Tracer uptake in 28 different kinds of cancer. In: Journal of Nuclear Medicine. 2019 ; Vol. 60, No. 6. pp. 801-805.
@article{92a07a9cdee5465b9613ffc1ed91f865,
title = "68Ga-FAPI PET/CT: Tracer uptake in 28 different kinds of cancer",
abstract = "The recent development of quinoline-based PET tracers that act as fibroblast-activation-protein inhibitors (FAPIs) demonstrated promising preclinical and clinical results. FAP is overexpressed by cancer-associated fibroblasts of several tumor entities. Here, we quantify the tumor uptake on 68Ga-FAPI PET/CT of various primary and metastatic tumors to identify the most promising indications for future application. Methods: 68Ga-FAPI PET/CT scans were requested by various referring physicians according to individual clinical indications that were considered insufficiently covered by 18F-FDG PET/CT or other imaging modalities. All PET/CT was performed 1 h after injection of 122–312 MBq of 68Ga-FAPI-04. We retrospectively identified 80 patients with histopathologically proven primary tumors or metastases or radiologically unequivocal metastatic lesions of histologically proven primary tumors. Tumor uptake was quantified by SUVmax and SUVmean (60{\%} isocontour). Results: Eighty patients with 28 different tumor entities (54 primary tumors and 229 metastases) were evaluated. The highest average SUVmax (.12) was found in sarcoma, esophageal, breast, cholangiocarcinoma, and lung cancer. The lowest 68Ga-FAPI uptake (average SUVmax, 6) was observed in pheochromocytoma, renal cell, differentiated thyroid, adenoid cystic, and gastric cancer. The average SUVmax of hepatocellular, colorectal, head–neck, ovarian, pancreatic, and prostate cancer was intermediate (SUV 6–12). SUV varied across and within all tumor entities. Because of low background in muscle and blood pool (SUVmax , 2), the tumor-to-background contrast ratios were more than 3-fold in the intermediate and more than 6-fold in the high-intensity uptake group. Conclusion: Several highly prevalent cancers presented with remarkably high uptake and image contrast on 68Ga-FAPI PET/CT. The high and rather selective tumor uptake may open up new applications for noninvasive tumor characterization, staging examinations, or radioligand therapy.",
keywords = "Breast cancer, Colorectal cancer, FAPI, Lung cancer, PET/CT",
author = "Clemens Kratochwil and Paul Flechsig and Thomas Lindner and Labidi Abderrahim and Annette Altmann and Walter Mier and Sebastian Adeberg and Hendrik Rathke and Manuel R{\"o}hrich and Hauke Winter and Plinkert, {Peter K.} and Frederik Marme and Matthias Lang and Kauczor, {Hans Ulrich} and Dirk J{\"a}ger and J{\"u}rgen Debus and Uwe Haberkorn and Giesel, {Frederik L.}",
year = "2019",
month = "6",
day = "1",
doi = "10.2967/jnumed.119.227967",
language = "English (US)",
volume = "60",
pages = "801--805",
journal = "Journal of Nuclear Medicine",
issn = "0161-5505",
publisher = "Society of Nuclear Medicine Inc.",
number = "6",

}

TY - JOUR

T1 - 68Ga-FAPI PET/CT

T2 - Tracer uptake in 28 different kinds of cancer

AU - Kratochwil, Clemens

AU - Flechsig, Paul

AU - Lindner, Thomas

AU - Abderrahim, Labidi

AU - Altmann, Annette

AU - Mier, Walter

AU - Adeberg, Sebastian

AU - Rathke, Hendrik

AU - Röhrich, Manuel

AU - Winter, Hauke

AU - Plinkert, Peter K.

AU - Marme, Frederik

AU - Lang, Matthias

AU - Kauczor, Hans Ulrich

AU - Jäger, Dirk

AU - Debus, Jürgen

AU - Haberkorn, Uwe

AU - Giesel, Frederik L.

PY - 2019/6/1

Y1 - 2019/6/1

N2 - The recent development of quinoline-based PET tracers that act as fibroblast-activation-protein inhibitors (FAPIs) demonstrated promising preclinical and clinical results. FAP is overexpressed by cancer-associated fibroblasts of several tumor entities. Here, we quantify the tumor uptake on 68Ga-FAPI PET/CT of various primary and metastatic tumors to identify the most promising indications for future application. Methods: 68Ga-FAPI PET/CT scans were requested by various referring physicians according to individual clinical indications that were considered insufficiently covered by 18F-FDG PET/CT or other imaging modalities. All PET/CT was performed 1 h after injection of 122–312 MBq of 68Ga-FAPI-04. We retrospectively identified 80 patients with histopathologically proven primary tumors or metastases or radiologically unequivocal metastatic lesions of histologically proven primary tumors. Tumor uptake was quantified by SUVmax and SUVmean (60% isocontour). Results: Eighty patients with 28 different tumor entities (54 primary tumors and 229 metastases) were evaluated. The highest average SUVmax (.12) was found in sarcoma, esophageal, breast, cholangiocarcinoma, and lung cancer. The lowest 68Ga-FAPI uptake (average SUVmax, 6) was observed in pheochromocytoma, renal cell, differentiated thyroid, adenoid cystic, and gastric cancer. The average SUVmax of hepatocellular, colorectal, head–neck, ovarian, pancreatic, and prostate cancer was intermediate (SUV 6–12). SUV varied across and within all tumor entities. Because of low background in muscle and blood pool (SUVmax , 2), the tumor-to-background contrast ratios were more than 3-fold in the intermediate and more than 6-fold in the high-intensity uptake group. Conclusion: Several highly prevalent cancers presented with remarkably high uptake and image contrast on 68Ga-FAPI PET/CT. The high and rather selective tumor uptake may open up new applications for noninvasive tumor characterization, staging examinations, or radioligand therapy.

AB - The recent development of quinoline-based PET tracers that act as fibroblast-activation-protein inhibitors (FAPIs) demonstrated promising preclinical and clinical results. FAP is overexpressed by cancer-associated fibroblasts of several tumor entities. Here, we quantify the tumor uptake on 68Ga-FAPI PET/CT of various primary and metastatic tumors to identify the most promising indications for future application. Methods: 68Ga-FAPI PET/CT scans were requested by various referring physicians according to individual clinical indications that were considered insufficiently covered by 18F-FDG PET/CT or other imaging modalities. All PET/CT was performed 1 h after injection of 122–312 MBq of 68Ga-FAPI-04. We retrospectively identified 80 patients with histopathologically proven primary tumors or metastases or radiologically unequivocal metastatic lesions of histologically proven primary tumors. Tumor uptake was quantified by SUVmax and SUVmean (60% isocontour). Results: Eighty patients with 28 different tumor entities (54 primary tumors and 229 metastases) were evaluated. The highest average SUVmax (.12) was found in sarcoma, esophageal, breast, cholangiocarcinoma, and lung cancer. The lowest 68Ga-FAPI uptake (average SUVmax, 6) was observed in pheochromocytoma, renal cell, differentiated thyroid, adenoid cystic, and gastric cancer. The average SUVmax of hepatocellular, colorectal, head–neck, ovarian, pancreatic, and prostate cancer was intermediate (SUV 6–12). SUV varied across and within all tumor entities. Because of low background in muscle and blood pool (SUVmax , 2), the tumor-to-background contrast ratios were more than 3-fold in the intermediate and more than 6-fold in the high-intensity uptake group. Conclusion: Several highly prevalent cancers presented with remarkably high uptake and image contrast on 68Ga-FAPI PET/CT. The high and rather selective tumor uptake may open up new applications for noninvasive tumor characterization, staging examinations, or radioligand therapy.

KW - Breast cancer

KW - Colorectal cancer

KW - FAPI

KW - Lung cancer

KW - PET/CT

UR - http://www.scopus.com/inward/record.url?scp=85066890000&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85066890000&partnerID=8YFLogxK

U2 - 10.2967/jnumed.119.227967

DO - 10.2967/jnumed.119.227967

M3 - Article

VL - 60

SP - 801

EP - 805

JO - Journal of Nuclear Medicine

JF - Journal of Nuclear Medicine

SN - 0161-5505

IS - 6

ER -